Filing Flows › Tela Bio (TELA) › Q1 2025
Tela Bio (TELA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Tela Bio (TELA) reported revenue of $18.5M for the first quarter 2025 (Q1 2025), +12% from a year earlier and +5% from the quarter before. Operating margin was -56.5%, net loss $11.3M (60.8% of revenue).
Tela Bio, Q1 2025: revenue $18.5M (+12% year over year), operating margin -56.5%, net loss $11.3M, operating cash flow −$9.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.5M | +5% | +12% |
| Operating profit | −$10.5M | — | — |
| Net earnings | −$11.3M | — | — |
| Operating cash flow | −$9.7M | — | — |
What changed
Revenue was $18.5M in Q1 2025, up 12% year over year and up 5% from the previous quarter.
Gross margin was 67.6%, down 0.7 points from a year earlier. Operating costs exceeded revenue by $10.5M, an operating margin of -56.5%. Operating expenses grew 42% against revenue growth of 12%. The quarter ended with a net loss of $11.3M, wider than the previous quarter's $9.2M loss.
Operating cash flow was −$9.7M. Non-cash charges added back $172K of depreciation and $1.0M of share-based compensation. Capital expenditures of $32K exceeded it, leaving free cash flow of −$9.8M.
Questions
What was Tela Bio's revenue in the first quarter 2025?
Tela Bio (TELA) reported revenue of $18.5M for the first quarter 2025 (Q1 2025), +12% from a year earlier and +5% from the quarter before.
Was Tela Bio profitable in the first quarter 2025?
Operating loss was $10.5M (-56.5% of revenue) and net loss $11.3M.
Source: Tela Bio 10-Q on SEC EDGAR.